Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5

Area of Science:

• Oncology
• Immunology
• Radiopharmaceuticals

Background:

• Melanoma metastasis detection remains a clinical challenge.
• Monoclonal antibodies offer targeted delivery for diagnostic imaging.

Purpose of the Study:

• To evaluate the efficacy of a radiolabeled monoclonal antibody (96.5) for in vivo imaging of malignant melanoma metastases.
• To determine optimal dosing for antibody-based melanoma detection.

Main Methods:

• Conjugation of monoclonal antibody 96.5 with diethylenetriaminepentaacetic acid and labeling with Indium-111 (111In).
• Administration of the radiolabeled antibody to 31 patients with metastatic melanoma.
• Total-body scanning at various intervals post-injection to assess imaging capabilities and specificity.

Main Results:

• No serious adverse effects were observed in patients receiving the antibody.
• 50% specificity was achieved in imaging previously documented metastatic sites.
• Increased antibody dosage correlated with a significant increase in the number of imaged metastatic sites.
• Optimal tumor visualization was observed between 48 to 72 hours post-administration, despite background uptake.

Conclusions:

• 111In-labeled monoclonal antibody 96.5 shows promise for in vivo melanoma metastasis imaging.
• Higher antibody doses (above 2 mg) appear crucial for improved detection rates.
• Further optimization may enhance specificity and reduce background interference.